Subsequently, however, the principle that HER2 targeted CAR T-cells could be safely administered systemically was demonstrated in sarcoma patients at doses of up to 1 × 108 cells/m2, infused initially without lymphodepletion [23]. Here, ERBB2 is linked to sarcoma.